Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.
Fiche du document
2015
- doi: 10.1186/s12879-015-1120-8
- issn: 1471-2334
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12879-015-1120-8
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/26392270
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1471-2334
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6B6E34494A377
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Tsʻeu Tzʻu Ci Tse Ribose nucleic acid Ribonucleic acidCiter ce document
J. Young et al., « Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. », Serveur académique Lausannois, ID : 10.1186/s12879-015-1120-8
Métriques
Partage / Export
Résumé
BACKGROUND: Temporary increases in plasma HIV RNA ('blips') are common in HIV patients on combination antiretroviral therapy (cART). Blips above 500 copies/mL have been associated with subsequent viral rebound. It is not clear if this relationship still holds when measurements are made using newer more sensitive assays. METHODS: We selected antiretroviral-naive patients that then recorded one or more episodes of viral suppression on cART with HIV RNA measurements made using more sensitive assays (lower limit of detection below 50 copies/ml). We estimated the association in these episodes between blip magnitude and the time to viral rebound. RESULTS: Four thousand ninety-four patients recorded a first episode of viral suppression on cART using more sensitive assays; 1672 patients recorded at least one subsequent suppression episode. Most suppression episodes (87 %) were recorded with TaqMan version 1 or 2 assays. Of the 2035 blips recorded, 84 %, 12 % and 4 % were of low (50-199 copies/mL), medium (200-499 copies/mL) and high (500-999 copies/mL) magnitude respectively. The risk of viral rebound increased as blip magnitude increased with hazard ratios of 1.20 (95 % CI 0.89-1.61), 1.42 (95 % CI 0.96-2.19) and 1.93 (95 % CI 1.24-3.01) for low, medium and high magnitude blips respectively; an increase of hazard ratio 1.09 (95 % CI 1.03 to 1.15) per 100 copies/mL of HIV RNA. CONCLUSIONS: With the more sensitive assays now commonly used for monitoring patients, blips above 200 copies/mL are increasingly likely to lead to viral rebound and should prompt a discussion about adherence.